Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc reports consumer health developments across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's news commonly covers product launches and brand activity for names such as Sensodyne, parodontax, Centrum, Advil, TUMS, Theraflu, Voltaren, Polident and Panadol.
Recurring updates include oral-care innovation, multivitamin research, consumer marketing campaigns, regional growth initiatives, manufacturing investment, and leadership changes within the U.S. and other markets. As a foreign issuer with American depositary shares traded under HLN, company announcements may also address parent-company reporting, governance and capital-market communications.
Haleon (HLN) was honored on December 12, 2025 as a 2025 Fast Company Brands That Matter honoree in the Family of Brands category. The recognition highlights Haleon’s portfolio-level impact, citing cultural relevance, meaningful consumer connection, and purpose-driven innovation across brands such as Sensodyne, Centrum, Advil, Voltaren, Emergen-C, and Theraflu. The company emphasized science-backed products, transparent communication, cross-brand collaboration, and consumer education as drivers of trust and emotional resonance. The award underscores Haleon’s stated mission to expand everyday health access by uniting diverse brands under a shared purpose.
Altibbi partnered with Haleon (HLN) on the Healthy Saudi Smile campaign, announced Nov 24, 2025, to turn oral-health awareness into actionable care across Saudi Arabia.
Altibbi provided Arabic-language, science-based education and connected users to certified doctors for instant consultations, supporting strong engagement and enabling thousands to receive trusted oral-health guidance. The campaign links brand purpose, local expertise, and digital access and aligns with preventive-health priorities in Saudi Vision 2030.
Altibbi plans to expand similar collaborations with health and wellness brands to combine education, access, and care.
Haleon (LSE/NYSE:HLN) announced on October 8, 2025 it selected Salesforce Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce to support its global sales organisation. The AI-powered rollout will cover Haleon's 4,500-strong sales force to improve engagement with pharmacies and healthcare professionals and to deliver data-driven insights on consumer demographics, shopping trends, and point-of-sale marketing.
Haleon will serve as a design partner to influence product availability, shelf-life management, promotions, and inventory features for consumer health use cases. The company said the change aims to reduce administrative time for reps and enable more bespoke activation plans for customers worldwide.
Aptar Pharma (NYSE:ATR) has announced a significant sustainability milestone with its Freepod® nasal spray pump, used in Haleon's Otrivin® brand, now being manufactured with 52% bio-based feedstock. This marks the first Aptar delivery system using such materials to be commercialized globally.
The innovative solution features an ISCC Plus certified manufacturing process, with the bottle produced using a mass balance approach equivalent to 100% bio-based content. Combined, the pump and bottle components achieve 60% circular material content for the complete nasal spray device. The manufacturing site in Mezzovico, Switzerland, maintains ISCC PLUS certification, ensuring complete material traceability.
This development supports Haleon's sustainability goals of reducing virgin petroleum-based plastic use by 10% by 2025 and by a third by 2030, compared to 2022 levels.
Haleon (NYSE:HLN) has initiated construction of its new £130 million Global Oral Health Innovation Centre in Weybridge, Surrey. The groundbreaking ceremony was attended by UK Minister Baroness Jones and marks a significant step in Haleon's mission to reach one billion more consumers by 2030.
The state-of-the-art facility will serve as the R&D epicenter for Haleon's oral health portfolio, featuring a digital immersive room for real-time collaboration with its Levice manufacturing site. The center has achieved a BREEAM® Outstanding rating for its sustainability design and will focus on developing solutions for unmet oral health needs globally.
Haleon (NYSE: HLN) has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025. Haney joins from Estée Lauder Companies Inc., where he served as Executive Vice President of Global Innovation and R&D for 13 years, following a 20-year tenure at P&G.
Haney succeeds Franck Riot, who is departing after six years with the company. CEO Brian McNamara highlighted Haney's expertise in driving transformative innovation within global consumer businesses, emphasizing his role in implementing Haleon's new Win as One strategy.
Summary not available.
TUMS has partnered with DraftKings to launch TUMS Fantasy Foodball Pool, a free online game where players can draft food and drink combinations for a chance to win from a $40,000 prize pool. The initiative comes as a survey reveals that 25% of viewers prioritize food during the big game, with 54% believing gameday food can make or break the experience.
The game features four rounds from January 6 to February 9, each focusing on different themes: Tailgate Foods, Spicy Foods, Sweet Foods, and New Orleans Foods. Players can select from 36 items, including popular gameday foods like barbecue (34%), hot wings (33%), and seven-layer dip (24%). Former football champion Vince Wilfork has joined as a partner to promote the initiative.
TUMS will also host a public event at Bourbon Heat in New Orleans on February 7, offering product samples and exclusive merchandise. The survey, conducted by Talker Research, included 2,000 Americans aged 21-43.
Haleon has appointed Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024. Sta-Romana, who previously led Unilever's Walmart business and has over 20 years of experience in the FMCG sector, will lead the organization's customer strategy and drive growth in the US market. In his new role, he will focus on implementing customer-focused strategies, improving data analytics, enhancing digital solutions, and building stronger partnerships with key retailers. The appointment aims to strengthen Haleon's position in delivering better everyday health solutions through improved customer relationships.
Haleon has launched Eroxon®, the first FDA-cleared over-the-counter gel for erectile dysfunction (ED) in the U.S. Available for pre-order on Amazon and in major retailers by October 2024, Eroxon® is clinically proven to help men achieve erections within 10 minutes. This fast-acting treatment addresses a significant unmet need, as existing prescription solutions can take up to an hour to work.
Clinical studies demonstrate Eroxon®'s safety and efficacy for men with ED. The gel stimulates nerve endings in the penis to aid in achieving and maintaining erections. Haleon aims to make this accessible treatment available to millions of American men affected by ED, emphasizing the importance of sexual health in overall wellness.